Hemab Therapeutics Holdings, Inc. (COAG)
NASDAQ:COAG
Want to see COAG full AI Analyst Report?
COAG Stock Chart & Stats
25.01
0.01(0.04%)
―
--
Day’s Range― - ―
52-Week Range23.48 - 36.61
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,705,410
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
COAG FAQ
What was Hemab Therapeutics Holdings, Inc.’s price range in the past 12 months?
Hemab Therapeutics Holdings, Inc. lowest stock price was 23.48 and its highest was 36.61 in the past 12 months.
What is Hemab Therapeutics Holdings, Inc.’s market cap?
Currently, no data Available
When is Hemab Therapeutics Holdings, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Hemab Therapeutics Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is Hemab Therapeutics Holdings, Inc. overvalued?
According to Wall Street analysts Hemab Therapeutics Holdings, Inc.’s price is currently Undervalued.
Does Hemab Therapeutics Holdings, Inc. pay dividends?
Hemab Therapeutics Holdings, Inc. does not currently pay dividends.
What is Hemab Therapeutics Holdings, Inc.’s EPS estimate?
Hemab Therapeutics Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hemab Therapeutics Holdings, Inc. have?
Hemab Therapeutics Holdings, Inc. has 46,705,410 shares outstanding.
What happened to Hemab Therapeutics Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Hemab Therapeutics Holdings, Inc.?
Currently, no hedge funds are holding shares in COAG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Ownership Overview
Options Prices
Currently, No data available
---